Want to see IN:VIYASH full AI Analyst Report?
Top Page
Viyash Scientific
(VIYASH)
Select Model
Select Model
Rating:59Neutral
Price Target:
₹278.00
▲(31.97% Upside)
Action:Reiterated
Date:08/21/26
The score is driven primarily by improving financial performance, including a sharp profitability rebound and significantly stronger leverage position, but is capped by weaker cash conversion and prior volatility in results. Technicals are neutral with modestly negative momentum near-term, and valuation is a key headwind due to the very high P/E.
Positive Factors
Revenue and Profitability Rebound
The sharp revenue acceleration and improved operating margins indicate stronger business scale and earnings potential. If sustained, better operating leverage can support durable profitability, although the recent rebound still requires further validation.
Negative Factors
Volatile Profitability Track Record
Recent profitability remains unproven across the cycle because the business experienced losses and negative EBIT margins shortly before the rebound. This history raises uncertainty about cost stability and whether current earnings can persist through weaker operating conditions.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue and Profitability Rebound
The sharp revenue acceleration and improved operating margins indicate stronger business scale and earnings potential. If sustained, better operating leverage can support durable profitability, although the recent rebound still requires further validation.
Read all positive factors
Viyash Scientific (VIYASH) vs. iShares MSCI India ETF (INDA)
Market Cap
₹115.06B
Dividend Yield0.22%
Average Volume (3M)562.07K
Price to Earnings (P/E)62.2
Beta (1Y)1.26
Revenue Growth96.48%
EPS Growth251.87%
CountryIN
Employees1,244
SectorGeneral
Sector StrengthN/A
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)4.19
Shares Outstanding439,907,600
10 Day Avg. Volume216,593
30 Day Avg. Volume562,069
Financial Highlights & Ratios
PEG Ratio0.12
Price to Book (P/B)2.72
Price to Sales (P/S)2.32
P/FCF Ratio61.41
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)8.55
Revenue Forecast (FY)₹38.99B
Viyash Scientific Business Overview & Revenue Model
Company Description
Viyash Scientific Limited is a global veterinary healthcare company with operations spanning Europe, Asia, and other international markets. It specializes in developing and supplying finished dosage forms for a range of therapeutic applications, i...
How the Company Makes Money
null...
Viyash Scientific Financial Statement Overview
Summary
Income Statement
68
Positive
Balance Sheet
78
Positive
Cash Flow
58
Neutral
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 31.49B | 34.20B | 15.51B | 13.66B | 14.18B | 14.10B |
| Gross Profit | 10.67B | 10.58B | 7.40B | 5.53B | 1.59B | 5.66B |
| EBITDA | 5.84B | 6.54B | 1.59B | 549.80M | -464.48M | 1.18B |
| Net Income | 1.71B | 1.77B | 218.80M | -358.69M | -1.21B | 409.55M |
Balance Sheet | ||||||
| Total Assets | 0.00 | 46.28B | 16.02B | 15.40B | 15.29B | 14.51B |
| Cash, Cash Equivalents and Short-Term Investments | 2.59B | 2.70B | 632.04M | 687.85M | 416.25M | 591.21M |
| Total Debt | 0.00 | 4.90B | 4.81B | 4.88B | 4.44B | 3.65B |
| Total Liabilities | -31.15B | 15.14B | 8.32B | 8.27B | 7.80B | 7.11B |
| Stockholders Equity | 31.15B | 29.11B | 7.04B | 6.57B | 6.99B | 6.92B |
Cash Flow | ||||||
| Free Cash Flow | 288.00M | 1.29B | 442.70M | -2.12M | -693.71M | -18.69M |
| Operating Cash Flow | 449.00M | 2.64B | 833.60M | 305.95M | 168.08M | 305.95M |
| Investing Cash Flow | -42.20M | -938.90M | -247.80M | -119.05M | -649.58M | -955.66M |
| Financing Cash Flow | -325.70M | -543.10M | -607.30M | 45.46M | 322.28M | 672.57M |
Viyash Scientific Technical Analysis
Negative
210.65
Price Trends
266.12
Negative
254.39
Positive
230.23
Positive
Market Momentum
-1.33
Positive
44.25
Neutral
31.55
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:VIYASH, the sentiment is Negative. The current price of 210.65 is below the 20-day moving average (MA) of 263.96, below the 50-day MA of 266.12, and below the 200-day MA of 230.23, indicating a neutral trend. The MACD of -1.33 indicates Positive momentum. The RSI at 44.25 is Neutral, neither overbought nor oversold. The STOCH value of 31.55 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:VIYASH.
Viyash Scientific Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
81 Outperform | ₹207.26B | 31.94 | ― | 0.25% | 15.01% | 17.73% | |
77 Outperform | ₹171.82B | 28.30 | ― | 0.36% | 7.93% | 21.51% | |
70 Outperform | ₹160.75B | 23.15 | ― | 1.47% | 14.12% | 14.98% | |
69 Neutral | ₹116.75B | 39.35 | ― | 0.40% | 9.18% | -14.57% | |
67 Neutral | ₹110.45B | 18.28 | ― | 0.41% | 7.28% | 68.82% | |
59 Neutral | ₹115.06B | 62.16 | ― | 0.22% | 96.48% | 251.87% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
* General Sector Average
IN:VIYASH
Viyash Scientific
260.90
78.55
43.08%
IN:AKUMS
Akums Drugs and Pharmaceuticals Limited
750.10
290.28
63.13%
IN:APLLTD
Alembic Pharmaceuticals Limited
816.90
-115.03
-12.34%
IN:CAPLIPOINT
Caplin Point Laboratories Limited
2,793.00
553.38
24.71%
IN:ALIVUS
Glenmark Life Sciences Limited
1,391.85
458.54
49.13%
IN:STAR
Strides Pharma Science Ltd
1,217.65
313.28
34.64%
Viyash Scientific Corporate Events
Viyash Scientific Publishes Q1 FY’27 Earnings Call Transcript for Investors
Aug 16, 2026
Viyash Scientific Limited has notified stock exchanges about the availability of its Q1 FY’27 earnings call transcript for the quarter ended June 30, 2026. The disclosure, made under Regulation 30 of India’s listing obligations framewo...
Viyash Scientific discloses SEBI warning on insider trading database compliance
Jul 7, 2026
Viyash Scientific Limited has disclosed that its former Company Secretary and Compliance Officer received an administrative warning letter from the Securities and Exchange Board of India regarding the maintenance of the company’s Structured ...
Viyash Scientific’s Alivira Unit to Acquire Italy’s BioForLife for EUR 16.98 Million
Jun 8, 2026
Viyash Scientific’s step-down wholly owned subsidiary, Alivira Animal Health Limited in Ireland, has signed a binding agreement to acquire 100% of Milan-based BioForLife Italia s.r.l., a marketer and distributor of veterinary products for co...
Viyash Scientific to Acquire Italy’s BioForLife, Bolstering European Pet Care Push
Jun 8, 2026
Viyash Scientific, via its subsidiary Alivira Animal Health, has agreed to acquire 100% of Milan-based BioForLife Italia for about ₹188 crore, marking a strategic entry into Italy, one of Europe’s largest and fastest-growing companion ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.